75d8 Search Results


96
Cell Signaling Technology Inc foxo3a 75d8 rabbit mab
IP6 regulates the <t>FOXO3/CCND1</t> signaling pathway in rats. (a) The relative mRNA expression levels of Hdac3 in the distal small intestine ( n = 6 per group). Values were normalized to Actb expression. (b) The relative mRNA expression levels of Foxo3 in the distal small intestine ( n = 6 per group). Values were normalized to Actb expression. (c) The relative mRNA expression levels of Ccnd1 in the distal small intestine ( n = 6 per group). Values were normalized to Actb expression. (d) Western blotting analysis of the mucosa of the distal small intestine was performed to detect the protein expression levels of HDAC3, H3K9AC, FOXO3, and CCND1. Histone H3 was used as an internal control. (e) Relative protein expression of HDAC3, H3K9AC, FOXO3, and CCND1 of the mucosa in the distal small intestine. Values are mean ± SEM; ns, not significant; ** P < 0.01, SBS group versus Sham group; # P < 0.05, ### P < 0.001, SBS + IP6 group versus SBS group.
Foxo3a 75d8 Rabbit Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/75d8/FoxO3a+Rabbit+mAb/pmc09899046-90-42-49
Average 96 stars, based on 1 article reviews
foxo3a 75d8 rabbit mab - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc rabbit anti total foxo3a
IP6 regulates the <t>FOXO3/CCND1</t> signaling pathway in rats. (a) The relative mRNA expression levels of Hdac3 in the distal small intestine ( n = 6 per group). Values were normalized to Actb expression. (b) The relative mRNA expression levels of Foxo3 in the distal small intestine ( n = 6 per group). Values were normalized to Actb expression. (c) The relative mRNA expression levels of Ccnd1 in the distal small intestine ( n = 6 per group). Values were normalized to Actb expression. (d) Western blotting analysis of the mucosa of the distal small intestine was performed to detect the protein expression levels of HDAC3, H3K9AC, FOXO3, and CCND1. Histone H3 was used as an internal control. (e) Relative protein expression of HDAC3, H3K9AC, FOXO3, and CCND1 of the mucosa in the distal small intestine. Values are mean ± SEM; ns, not significant; ** P < 0.01, SBS group versus Sham group; # P < 0.05, ### P < 0.001, SBS + IP6 group versus SBS group.
Rabbit Anti Total Foxo3a, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/75d8/Phospho-FoxO3a+(Ser253)+Antibody/pmc02810006-98-27-67
Average 96 stars, based on 1 article reviews
rabbit anti total foxo3a - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc anti foxo3a
IP6 regulates the <t>FOXO3/CCND1</t> signaling pathway in rats. (a) The relative mRNA expression levels of Hdac3 in the distal small intestine ( n = 6 per group). Values were normalized to Actb expression. (b) The relative mRNA expression levels of Foxo3 in the distal small intestine ( n = 6 per group). Values were normalized to Actb expression. (c) The relative mRNA expression levels of Ccnd1 in the distal small intestine ( n = 6 per group). Values were normalized to Actb expression. (d) Western blotting analysis of the mucosa of the distal small intestine was performed to detect the protein expression levels of HDAC3, H3K9AC, FOXO3, and CCND1. Histone H3 was used as an internal control. (e) Relative protein expression of HDAC3, H3K9AC, FOXO3, and CCND1 of the mucosa in the distal small intestine. Values are mean ± SEM; ns, not significant; ** P < 0.01, SBS group versus Sham group; # P < 0.05, ### P < 0.001, SBS + IP6 group versus SBS group.
Anti Foxo3a, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/75d8/FoxO1+Rabbit+mAb/pmc05311243-266-26-30
Average 96 stars, based on 1 article reviews
anti foxo3a - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc resource source identifier antibodies rabbit monoclonal foxo3a cell signaling technology
(A) (left) HCT116 p53 −/− cells were transduced with two different lentiviral shRNAs targeting <t>FOXO3a</t> transcripts. After 24hrs of vehicle or bafilomycin A1 10nM treatment, PUMA mRNA levels were measured relative to 18s rRNA control. (right) western blot showing FOXO3a protein levels after treatment with two independent shRNAs targeting FOXO3a or shCtrl.
Resource Source Identifier Antibodies Rabbit Monoclonal Foxo3a Cell Signaling Technology, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/75d8/Atg5+Rabbit+mAb/pmc05866042-390-17-24
Average 95 stars, based on 1 article reviews
resource source identifier antibodies rabbit monoclonal foxo3a cell signaling technology - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

93
Novus Biologicals foxo3 cst 75d8 flag sigma aldrich f1804 ha roche 11583816001 actin novus nb100 74340 γh2ax millipore sigma
(A) (left) HCT116 p53 −/− cells were transduced with two different lentiviral shRNAs targeting <t>FOXO3a</t> transcripts. After 24hrs of vehicle or bafilomycin A1 10nM treatment, PUMA mRNA levels were measured relative to 18s rRNA control. (right) western blot showing FOXO3a protein levels after treatment with two independent shRNAs targeting FOXO3a or shCtrl.
Foxo3 Cst 75d8 Flag Sigma Aldrich F1804 Ha Roche 11583816001 Actin Novus Nb100 74340 γh2ax Millipore Sigma, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/75d8/Actin+Antibody+(mAbGEa)/10__1038_slash_s42003___026___11174___z-397-15-26
Average 93 stars, based on 1 article reviews
foxo3 cst 75d8 flag sigma aldrich f1804 ha roche 11583816001 actin novus nb100 74340 γh2ax millipore sigma - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc rabbit monoclonal
(A) FOXO3a full-length structure (top) showing relevant domains and truncated mutant forms (ΔCR1, ΔFH, ΔCR2C and ΔCR3). FOXO3a is composed by three conserved regions: CR1, CR2 and CR3 known to interact with several proteins. CR2 is divided in three subregions: CR2A, CR2B and CR2C. FOXO3a contains a Forkhead (FH) or DNA binding domain, that recognizes a TGTTTAC consensus DNA sequence, followed by a nuclear localization sequence (NLS). (B) Western blotting showing endogen FOXO3a downregulation, FOXO3a fulllength rescue and expression of FOXO3a truncated proteins. FOXO3a-Cell Signaling Technologies #2497 <t>monoclonal</t> antibody does not recognize ΔCR1 form because its epitope surrounds Glu50 (N-terminal). Cells were transduced 5 days with lentiviruses and the last 3 days transfected with siRNA. GAPDH was used as loading control. (C) sTIF quantification in siFOXO3a + truncated FOXO3a overexpression in BJ-HELT treated with bleomycin (50 μg/mL, 24hr), n=3. Conditions were compared to siFOXO3a-FOXO3a+Bleo using a Kruskal-Wallis’ multiple comparisons test. siFOXO3a-FOXO3a+Bleo vs siFOXO3a-△CR2C+Bleo , p-value =0,0345. (D) PLA showing TRF2-FOXO3a association in siFOXO3a + truncated FOXO3a overexpression in BJ-HELT treated with bleomycin (50 μg/mL, 24hr), n=3. (E) TRF2-FOXO3a PLA in transfected BJ-HELT cells treated with bleomycin, n=2. Statistical analyses were performed using Kruskal-Wallis’ multiple comparisons test (* p < 0.05, ** p < 0.001, *** p < 0.001, **** p < 0.0001). (F) Telomere specific damage upon p300 inhibition. siCtrl and sip300 transfected BJ-HELT cells were treated with bleomycin. Means ± SEM of two replicated are shown, Man-Whitney U test ( p-value= 0,0346).
Rabbit Monoclonal, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/75d8/GAPDH+Rabbit+mAb/bio_rxiv__2021__08__04__454762-193-21-26
Average 96 stars, based on 1 article reviews
rabbit monoclonal - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc foxo3a
Figure 3. <t>FOXO3a</t> negatively regulates PRNP expression at both the mRNA and protein levels. (A) Over-expression of FOXO1 (lane 2) and FOXO3a (lane 3), as detected by western blotting, induced a reduction of PrP protein levels in HeLa cells. (B) Western blotting showing that IGF-1 and LY294002 have an opposite function on the decrease of PrP protein levels induced by FOXO proteins over-expression. LY294002 treatment enhanced the reduction of PrP protein levels triggered by FOXO proteins, especially FOXO3a (lanes 1, 2 and 3). However, 100 ng/ml IGF-1 treatment impaired the negative regulation of FOXO proteins on PRNP (lanes 4, 5 and 6). (C) and (D) Western blotting and real-time PCR showing the efficiency of siFOXO1 and siFOXO3a in HeLa cells. Compared with the negative control groups, FOXO1 and FOXO3a were efficiently knocked-down. All experiments were performed at least three times, and the data were analyzed as the mean 6 S.E.M. (P,0.05). (E) and (F) Western blotting and real- time quantitative PCR showing that the knock-down of FOXO1 and FOXO3a by targeted siRNAs affects PRNP expression at both the protein and mRNA levels. Compared with the negative control group, the knock-down of FOXO3a increased the PrPC protein level remarkably, after normalization to actin, whereas the knock-down of FOXO1 had only a slight effect on the PrPC protein level. A similar result was obtained at the mRNA level. All experiments were performed at least three times, and the data were analyzed as the mean 6 S.E.M. (P,0.05). doi:10.1371/journal.pone.0071896.g003
Foxo3a, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/75d8/Phospho-FoxO1+(Thr24)%2FFoxO3a+(Thr32)+Antibody/pm23967259-72-54-55
Average 96 stars, based on 1 article reviews
foxo3a - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc rabbit monoclonal anti foxo3a 75d8
KEY RESOURCES TABLE
Rabbit Monoclonal Anti Foxo3a 75d8, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/75d8/Thalidomide/pmc06579120-8-0-5
Average 93 stars, based on 1 article reviews
rabbit monoclonal anti foxo3a 75d8 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc foxo3a 75d8
KEY RESOURCES TABLE
Foxo3a 75d8, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/75d8/Phospho-NF-kappaB+p65+(Ser536)+Antibody/pm31891805-47-2-10
Average 96 stars, based on 1 article reviews
foxo3a 75d8 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology antibodies against vitronectin 65 75
Quantitative proteomics by the Tandem Mass Tag (TMT) method
Antibodies Against Vitronectin 65 75, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/75d8/Vitronectin+65%2F75+Antibody/pmc06217763-73-0-13
Average 93 stars, based on 1 article reviews
antibodies against vitronectin 65 75 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


IP6 regulates the FOXO3/CCND1 signaling pathway in rats. (a) The relative mRNA expression levels of Hdac3 in the distal small intestine ( n = 6 per group). Values were normalized to Actb expression. (b) The relative mRNA expression levels of Foxo3 in the distal small intestine ( n = 6 per group). Values were normalized to Actb expression. (c) The relative mRNA expression levels of Ccnd1 in the distal small intestine ( n = 6 per group). Values were normalized to Actb expression. (d) Western blotting analysis of the mucosa of the distal small intestine was performed to detect the protein expression levels of HDAC3, H3K9AC, FOXO3, and CCND1. Histone H3 was used as an internal control. (e) Relative protein expression of HDAC3, H3K9AC, FOXO3, and CCND1 of the mucosa in the distal small intestine. Values are mean ± SEM; ns, not significant; ** P < 0.01, SBS group versus Sham group; # P < 0.05, ### P < 0.001, SBS + IP6 group versus SBS group.

Journal: Food & Nutrition Research

Article Title: Inositol hexaphosphate promotes intestinal adaptation in short bowel syndrome via an HDAC3-mediated epigenetic pathway

doi: 10.29219/fnr.v67.8694

Figure Lengend Snippet: IP6 regulates the FOXO3/CCND1 signaling pathway in rats. (a) The relative mRNA expression levels of Hdac3 in the distal small intestine ( n = 6 per group). Values were normalized to Actb expression. (b) The relative mRNA expression levels of Foxo3 in the distal small intestine ( n = 6 per group). Values were normalized to Actb expression. (c) The relative mRNA expression levels of Ccnd1 in the distal small intestine ( n = 6 per group). Values were normalized to Actb expression. (d) Western blotting analysis of the mucosa of the distal small intestine was performed to detect the protein expression levels of HDAC3, H3K9AC, FOXO3, and CCND1. Histone H3 was used as an internal control. (e) Relative protein expression of HDAC3, H3K9AC, FOXO3, and CCND1 of the mucosa in the distal small intestine. Values are mean ± SEM; ns, not significant; ** P < 0.01, SBS group versus Sham group; # P < 0.05, ### P < 0.001, SBS + IP6 group versus SBS group.

Article Snippet: The primary antibodies used in this study included anti-histone H3 antibody (1:1000, Cat# ab1791, Abcam, UK), anti-cyclin D1 (1:200, Cat# ab16663, Abcam, UK), HDAC3 antibody (1:1000, Cat# AF5349-50 μL, Affinity, China), anti-histone H3 (acetyl K9) antibody (1:500, Cat# ab32129, Abcam, UK), and FoxO3a (75D8) rabbit mAb (1:1000, Cat# 2497S, Cell Signaling Technology, USA).

Techniques: Expressing, Western Blot, Control

IP3 regulates the FOXO3/CCND1 signaling pathway in IEC-6 cells. (a) Western blotting analysis of IEC-6 cells was performed to detect the protein expression levels of HDAC3, H3K9AC, FOXO3, and CCND1. Histone H3 was used as an internal control. (b) Relative protein expression of HDAC3, H3K9AC, FOXO3, and CCND1 of the mucosa in the distal small intestine. Values are mean ± SEM; ns, not significant; * P < 0.05, ** P < 0.01, **** P < 0.0001, SBS group versus Sham group; # P < 0.05, ## P < 0.01, SBS + IP6 group versus SBS group.

Journal: Food & Nutrition Research

Article Title: Inositol hexaphosphate promotes intestinal adaptation in short bowel syndrome via an HDAC3-mediated epigenetic pathway

doi: 10.29219/fnr.v67.8694

Figure Lengend Snippet: IP3 regulates the FOXO3/CCND1 signaling pathway in IEC-6 cells. (a) Western blotting analysis of IEC-6 cells was performed to detect the protein expression levels of HDAC3, H3K9AC, FOXO3, and CCND1. Histone H3 was used as an internal control. (b) Relative protein expression of HDAC3, H3K9AC, FOXO3, and CCND1 of the mucosa in the distal small intestine. Values are mean ± SEM; ns, not significant; * P < 0.05, ** P < 0.01, **** P < 0.0001, SBS group versus Sham group; # P < 0.05, ## P < 0.01, SBS + IP6 group versus SBS group.

Article Snippet: The primary antibodies used in this study included anti-histone H3 antibody (1:1000, Cat# ab1791, Abcam, UK), anti-cyclin D1 (1:200, Cat# ab16663, Abcam, UK), HDAC3 antibody (1:1000, Cat# AF5349-50 μL, Affinity, China), anti-histone H3 (acetyl K9) antibody (1:500, Cat# ab32129, Abcam, UK), and FoxO3a (75D8) rabbit mAb (1:1000, Cat# 2497S, Cell Signaling Technology, USA).

Techniques: Western Blot, Expressing, Control

(A) (left) HCT116 p53 −/− cells were transduced with two different lentiviral shRNAs targeting FOXO3a transcripts. After 24hrs of vehicle or bafilomycin A1 10nM treatment, PUMA mRNA levels were measured relative to 18s rRNA control. (right) western blot showing FOXO3a protein levels after treatment with two independent shRNAs targeting FOXO3a or shCtrl.

Journal: Developmental cell

Article Title: Autophagy inhibition mediates apoptosis sensitization in cancer therapy by relieving FOXO3a turnover

doi: 10.1016/j.devcel.2018.02.014

Figure Lengend Snippet: (A) (left) HCT116 p53 −/− cells were transduced with two different lentiviral shRNAs targeting FOXO3a transcripts. After 24hrs of vehicle or bafilomycin A1 10nM treatment, PUMA mRNA levels were measured relative to 18s rRNA control. (right) western blot showing FOXO3a protein levels after treatment with two independent shRNAs targeting FOXO3a or shCtrl.

Article Snippet: Primers are listed in the . table ft1 table-wrap mode="anchored" t5 Table 1 caption a7 REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Rabbit monoclonal FOXO3a Cell Signaling Technology Cat# 3938, RRID:AB_2106669 Rabbit monoclonal ATG7 Cell Signaling Technology Cat# 8558, RRID:AB_10831194 Rabbit monoclonal ATG5 Cell Signaling Technology Cat# 9980S, RRID:AB_10829153 Rabbit polyclonal PUMA/BBC3 Cell Signaling Technology Cat# 4976, RRID:AB_2064551) Rabbit polyclonal ULK1 Cell Signaling Technology Cat# 4773S, RRID:AB_2288252 Rabbit polyclonal PI3 Kinase Class III Cell Signaling Technology Cat# 3811S, RRID:AB_2062856 Rabbit polyclonal LC3 Novus Cat# NB100-2220, RRID:AB_10003146 Mouse monoclonal beta-Actin Sigma-Aldrich Cat# A5441, RRID:AB_476744 Mouse monoclonal p62/SQSTM1 Novus Cat# H00008878-M01, RRID:AB_548364 Mouse monoclonal Purified anti-RNA Polymerase II RPB1 antibody Clone H5 Biolegend Cat# 920204, RRID:AB_2616695 Bacterial and Virus Strains Biological Samples Chemicals, Peptides, and Recombinant Proteins Bafilomycin A1 Sigma-Aldrich B1792; CAS RN: 88899-55-2 Chloroquine MP Biomedicals 93919; CAS RN: 50-63-5 Nutlin-3a Cayman Chemicals 10004372; CAS RN: 548472-68-0 Protease inhibitor cocktail Roche 11836153001 Phosphatase inhibitor Sigma-Aldrich P5726 Protein A/G Plus beads Santa Cruz SC-2003 Critical Commercial Assays Qiagen RNeasy RNA isolation kit Qiagen Cat# 74104 QuantiTect Reverse Transcription Kit Qiagen Cat# 205311 Deposited Data Experimental Models: Cell Lines HCT116 Authenticated N/A MCF7 Authenticated N/A MCF10a Authenticated N/A HeLa N/A Experimental Models: Organisms/Strains Oligonucleotides See Table S1 for ChIP primers This paper N/A See Table S1 for QPCR primers This paper N/A See Table S1 for gRNAs This paper N/A Recombinant DNA pBABE puro mCherry-GFP-HA-FOXO3a This paper and Addgene x 2 #1787 and #1764 Software and Algorithms Other SYBR Green CFX for QPCR Applied Biosystems 4472942 Mirus Transit LT1 transfection reagent Mirus MIR2304 CRISPR Max ThermoFisher CMAX00001 Cell Event Caspase 3/7 Invitrogen C10423 MatTek 35mm dishes for living imaging MatTek P35GC-1.5-14-C LysoTracker Blue DND-22 ThermoFisher Cat# L7525 Incucyte ZOOM imaging system Essen BioScience N/A Open in a separate window KEY RESOURCES TABLE Expression constructs, shRNAs, and transduction Protein depletion by shRNA was achieved by using the pLKO.1 system.

Techniques: Transduction, Western Blot

(A) HCT116 cells treated with bafilomycin A1 10nM, an autophagy inhibitor, for indicated duration. Whole-cell lysates were probed for FOXO3a protein levels. See also Figure S3.

Journal: Developmental cell

Article Title: Autophagy inhibition mediates apoptosis sensitization in cancer therapy by relieving FOXO3a turnover

doi: 10.1016/j.devcel.2018.02.014

Figure Lengend Snippet: (A) HCT116 cells treated with bafilomycin A1 10nM, an autophagy inhibitor, for indicated duration. Whole-cell lysates were probed for FOXO3a protein levels. See also Figure S3.

Article Snippet: Primers are listed in the . table ft1 table-wrap mode="anchored" t5 Table 1 caption a7 REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Rabbit monoclonal FOXO3a Cell Signaling Technology Cat# 3938, RRID:AB_2106669 Rabbit monoclonal ATG7 Cell Signaling Technology Cat# 8558, RRID:AB_10831194 Rabbit monoclonal ATG5 Cell Signaling Technology Cat# 9980S, RRID:AB_10829153 Rabbit polyclonal PUMA/BBC3 Cell Signaling Technology Cat# 4976, RRID:AB_2064551) Rabbit polyclonal ULK1 Cell Signaling Technology Cat# 4773S, RRID:AB_2288252 Rabbit polyclonal PI3 Kinase Class III Cell Signaling Technology Cat# 3811S, RRID:AB_2062856 Rabbit polyclonal LC3 Novus Cat# NB100-2220, RRID:AB_10003146 Mouse monoclonal beta-Actin Sigma-Aldrich Cat# A5441, RRID:AB_476744 Mouse monoclonal p62/SQSTM1 Novus Cat# H00008878-M01, RRID:AB_548364 Mouse monoclonal Purified anti-RNA Polymerase II RPB1 antibody Clone H5 Biolegend Cat# 920204, RRID:AB_2616695 Bacterial and Virus Strains Biological Samples Chemicals, Peptides, and Recombinant Proteins Bafilomycin A1 Sigma-Aldrich B1792; CAS RN: 88899-55-2 Chloroquine MP Biomedicals 93919; CAS RN: 50-63-5 Nutlin-3a Cayman Chemicals 10004372; CAS RN: 548472-68-0 Protease inhibitor cocktail Roche 11836153001 Phosphatase inhibitor Sigma-Aldrich P5726 Protein A/G Plus beads Santa Cruz SC-2003 Critical Commercial Assays Qiagen RNeasy RNA isolation kit Qiagen Cat# 74104 QuantiTect Reverse Transcription Kit Qiagen Cat# 205311 Deposited Data Experimental Models: Cell Lines HCT116 Authenticated N/A MCF7 Authenticated N/A MCF10a Authenticated N/A HeLa N/A Experimental Models: Organisms/Strains Oligonucleotides See Table S1 for ChIP primers This paper N/A See Table S1 for QPCR primers This paper N/A See Table S1 for gRNAs This paper N/A Recombinant DNA pBABE puro mCherry-GFP-HA-FOXO3a This paper and Addgene x 2 #1787 and #1764 Software and Algorithms Other SYBR Green CFX for QPCR Applied Biosystems 4472942 Mirus Transit LT1 transfection reagent Mirus MIR2304 CRISPR Max ThermoFisher CMAX00001 Cell Event Caspase 3/7 Invitrogen C10423 MatTek 35mm dishes for living imaging MatTek P35GC-1.5-14-C LysoTracker Blue DND-22 ThermoFisher Cat# L7525 Incucyte ZOOM imaging system Essen BioScience N/A Open in a separate window KEY RESOURCES TABLE Expression constructs, shRNAs, and transduction Protein depletion by shRNA was achieved by using the pLKO.1 system.

Techniques:

KEY RESOURCES TABLE

Journal: Developmental cell

Article Title: Autophagy inhibition mediates apoptosis sensitization in cancer therapy by relieving FOXO3a turnover

doi: 10.1016/j.devcel.2018.02.014

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Primers are listed in the . table ft1 table-wrap mode="anchored" t5 Table 1 caption a7 REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Rabbit monoclonal FOXO3a Cell Signaling Technology Cat# 3938, RRID:AB_2106669 Rabbit monoclonal ATG7 Cell Signaling Technology Cat# 8558, RRID:AB_10831194 Rabbit monoclonal ATG5 Cell Signaling Technology Cat# 9980S, RRID:AB_10829153 Rabbit polyclonal PUMA/BBC3 Cell Signaling Technology Cat# 4976, RRID:AB_2064551) Rabbit polyclonal ULK1 Cell Signaling Technology Cat# 4773S, RRID:AB_2288252 Rabbit polyclonal PI3 Kinase Class III Cell Signaling Technology Cat# 3811S, RRID:AB_2062856 Rabbit polyclonal LC3 Novus Cat# NB100-2220, RRID:AB_10003146 Mouse monoclonal beta-Actin Sigma-Aldrich Cat# A5441, RRID:AB_476744 Mouse monoclonal p62/SQSTM1 Novus Cat# H00008878-M01, RRID:AB_548364 Mouse monoclonal Purified anti-RNA Polymerase II RPB1 antibody Clone H5 Biolegend Cat# 920204, RRID:AB_2616695 Bacterial and Virus Strains Biological Samples Chemicals, Peptides, and Recombinant Proteins Bafilomycin A1 Sigma-Aldrich B1792; CAS RN: 88899-55-2 Chloroquine MP Biomedicals 93919; CAS RN: 50-63-5 Nutlin-3a Cayman Chemicals 10004372; CAS RN: 548472-68-0 Protease inhibitor cocktail Roche 11836153001 Phosphatase inhibitor Sigma-Aldrich P5726 Protein A/G Plus beads Santa Cruz SC-2003 Critical Commercial Assays Qiagen RNeasy RNA isolation kit Qiagen Cat# 74104 QuantiTect Reverse Transcription Kit Qiagen Cat# 205311 Deposited Data Experimental Models: Cell Lines HCT116 Authenticated N/A MCF7 Authenticated N/A MCF10a Authenticated N/A HeLa N/A Experimental Models: Organisms/Strains Oligonucleotides See Table S1 for ChIP primers This paper N/A See Table S1 for QPCR primers This paper N/A See Table S1 for gRNAs This paper N/A Recombinant DNA pBABE puro mCherry-GFP-HA-FOXO3a This paper and Addgene x 2 #1787 and #1764 Software and Algorithms Other SYBR Green CFX for QPCR Applied Biosystems 4472942 Mirus Transit LT1 transfection reagent Mirus MIR2304 CRISPR Max ThermoFisher CMAX00001 Cell Event Caspase 3/7 Invitrogen C10423 MatTek 35mm dishes for living imaging MatTek P35GC-1.5-14-C LysoTracker Blue DND-22 ThermoFisher Cat# L7525 Incucyte ZOOM imaging system Essen BioScience N/A Open in a separate window KEY RESOURCES TABLE Expression constructs, shRNAs, and transduction Protein depletion by shRNA was achieved by using the pLKO.1 system.

Techniques: Purification, Recombinant, Protease Inhibitor, Isolation, Software, SYBR Green Assay, Transfection, CRISPR, Imaging

(A) FOXO3a full-length structure (top) showing relevant domains and truncated mutant forms (ΔCR1, ΔFH, ΔCR2C and ΔCR3). FOXO3a is composed by three conserved regions: CR1, CR2 and CR3 known to interact with several proteins. CR2 is divided in three subregions: CR2A, CR2B and CR2C. FOXO3a contains a Forkhead (FH) or DNA binding domain, that recognizes a TGTTTAC consensus DNA sequence, followed by a nuclear localization sequence (NLS). (B) Western blotting showing endogen FOXO3a downregulation, FOXO3a fulllength rescue and expression of FOXO3a truncated proteins. FOXO3a-Cell Signaling Technologies #2497 monoclonal antibody does not recognize ΔCR1 form because its epitope surrounds Glu50 (N-terminal). Cells were transduced 5 days with lentiviruses and the last 3 days transfected with siRNA. GAPDH was used as loading control. (C) sTIF quantification in siFOXO3a + truncated FOXO3a overexpression in BJ-HELT treated with bleomycin (50 μg/mL, 24hr), n=3. Conditions were compared to siFOXO3a-FOXO3a+Bleo using a Kruskal-Wallis’ multiple comparisons test. siFOXO3a-FOXO3a+Bleo vs siFOXO3a-△CR2C+Bleo , p-value =0,0345. (D) PLA showing TRF2-FOXO3a association in siFOXO3a + truncated FOXO3a overexpression in BJ-HELT treated with bleomycin (50 μg/mL, 24hr), n=3. (E) TRF2-FOXO3a PLA in transfected BJ-HELT cells treated with bleomycin, n=2. Statistical analyses were performed using Kruskal-Wallis’ multiple comparisons test (* p < 0.05, ** p < 0.001, *** p < 0.001, **** p < 0.0001). (F) Telomere specific damage upon p300 inhibition. siCtrl and sip300 transfected BJ-HELT cells were treated with bleomycin. Means ± SEM of two replicated are shown, Man-Whitney U test ( p-value= 0,0346).

Journal: bioRxiv

Article Title: Specific telomere protection ensured by FOXO3a upon genotoxic stress and during aging

doi: 10.1101/2021.08.04.454762

Figure Lengend Snippet: (A) FOXO3a full-length structure (top) showing relevant domains and truncated mutant forms (ΔCR1, ΔFH, ΔCR2C and ΔCR3). FOXO3a is composed by three conserved regions: CR1, CR2 and CR3 known to interact with several proteins. CR2 is divided in three subregions: CR2A, CR2B and CR2C. FOXO3a contains a Forkhead (FH) or DNA binding domain, that recognizes a TGTTTAC consensus DNA sequence, followed by a nuclear localization sequence (NLS). (B) Western blotting showing endogen FOXO3a downregulation, FOXO3a fulllength rescue and expression of FOXO3a truncated proteins. FOXO3a-Cell Signaling Technologies #2497 monoclonal antibody does not recognize ΔCR1 form because its epitope surrounds Glu50 (N-terminal). Cells were transduced 5 days with lentiviruses and the last 3 days transfected with siRNA. GAPDH was used as loading control. (C) sTIF quantification in siFOXO3a + truncated FOXO3a overexpression in BJ-HELT treated with bleomycin (50 μg/mL, 24hr), n=3. Conditions were compared to siFOXO3a-FOXO3a+Bleo using a Kruskal-Wallis’ multiple comparisons test. siFOXO3a-FOXO3a+Bleo vs siFOXO3a-△CR2C+Bleo , p-value =0,0345. (D) PLA showing TRF2-FOXO3a association in siFOXO3a + truncated FOXO3a overexpression in BJ-HELT treated with bleomycin (50 μg/mL, 24hr), n=3. (E) TRF2-FOXO3a PLA in transfected BJ-HELT cells treated with bleomycin, n=2. Statistical analyses were performed using Kruskal-Wallis’ multiple comparisons test (* p < 0.05, ** p < 0.001, *** p < 0.001, **** p < 0.0001). (F) Telomere specific damage upon p300 inhibition. siCtrl and sip300 transfected BJ-HELT cells were treated with bleomycin. Means ± SEM of two replicated are shown, Man-Whitney U test ( p-value= 0,0346).

Article Snippet: The following primary antibodies were used: TRF2, mouse monoclonal, (NB100-56506, 1:1000, Novus Biologicals); TRF2, rabbit monoclonal, (NB110-57130, 1:5000, Novus Biologicals); FOXO3a, rabbit monoclonal (clone 75D8, 1:1500, Cell Signaling Technology); GAPDH, rabbit polyclonal (1:2000, NB100-56875, Novus Biologicals).

Techniques: Mutagenesis, Binding Assay, Sequencing, Western Blot, Expressing, Transfection, Control, Over Expression, Inhibition

Figure 3. FOXO3a negatively regulates PRNP expression at both the mRNA and protein levels. (A) Over-expression of FOXO1 (lane 2) and FOXO3a (lane 3), as detected by western blotting, induced a reduction of PrP protein levels in HeLa cells. (B) Western blotting showing that IGF-1 and LY294002 have an opposite function on the decrease of PrP protein levels induced by FOXO proteins over-expression. LY294002 treatment enhanced the reduction of PrP protein levels triggered by FOXO proteins, especially FOXO3a (lanes 1, 2 and 3). However, 100 ng/ml IGF-1 treatment impaired the negative regulation of FOXO proteins on PRNP (lanes 4, 5 and 6). (C) and (D) Western blotting and real-time PCR showing the efficiency of siFOXO1 and siFOXO3a in HeLa cells. Compared with the negative control groups, FOXO1 and FOXO3a were efficiently knocked-down. All experiments were performed at least three times, and the data were analyzed as the mean 6 S.E.M. (P,0.05). (E) and (F) Western blotting and real- time quantitative PCR showing that the knock-down of FOXO1 and FOXO3a by targeted siRNAs affects PRNP expression at both the protein and mRNA levels. Compared with the negative control group, the knock-down of FOXO3a increased the PrPC protein level remarkably, after normalization to actin, whereas the knock-down of FOXO1 had only a slight effect on the PrPC protein level. A similar result was obtained at the mRNA level. All experiments were performed at least three times, and the data were analyzed as the mean 6 S.E.M. (P,0.05). doi:10.1371/journal.pone.0071896.g003

Journal: PloS one

Article Title: IGF-1-induced enhancement of PRNP expression depends on the negative regulation of transcription factor FOXO3a.

doi: 10.1371/journal.pone.0071896

Figure Lengend Snippet: Figure 3. FOXO3a negatively regulates PRNP expression at both the mRNA and protein levels. (A) Over-expression of FOXO1 (lane 2) and FOXO3a (lane 3), as detected by western blotting, induced a reduction of PrP protein levels in HeLa cells. (B) Western blotting showing that IGF-1 and LY294002 have an opposite function on the decrease of PrP protein levels induced by FOXO proteins over-expression. LY294002 treatment enhanced the reduction of PrP protein levels triggered by FOXO proteins, especially FOXO3a (lanes 1, 2 and 3). However, 100 ng/ml IGF-1 treatment impaired the negative regulation of FOXO proteins on PRNP (lanes 4, 5 and 6). (C) and (D) Western blotting and real-time PCR showing the efficiency of siFOXO1 and siFOXO3a in HeLa cells. Compared with the negative control groups, FOXO1 and FOXO3a were efficiently knocked-down. All experiments were performed at least three times, and the data were analyzed as the mean 6 S.E.M. (P,0.05). (E) and (F) Western blotting and real- time quantitative PCR showing that the knock-down of FOXO1 and FOXO3a by targeted siRNAs affects PRNP expression at both the protein and mRNA levels. Compared with the negative control group, the knock-down of FOXO3a increased the PrPC protein level remarkably, after normalization to actin, whereas the knock-down of FOXO1 had only a slight effect on the PrPC protein level. A similar result was obtained at the mRNA level. All experiments were performed at least three times, and the data were analyzed as the mean 6 S.E.M. (P,0.05). doi:10.1371/journal.pone.0071896.g003

Article Snippet: Blocked with 5% nonfat milk in TBST (10 mM Tris, 150 mM NaCl, 0.1% Tween-20, pH 7.4) for 1 hour, the membrane was then incubated with specific primary antibodies over night at 4uC (i.e., a 1:1000 dilution of the anti-PrP monoclonal antibody 8H4 [Abcam, ab61409]; 1:1000 dilutions of monoclonal antibodies against FOXO1 [Beyotime, AF603], FOXO3a [Cell Signaling Technology, 75D8], phosphorylated FOXO1-Thr-24/FOXO3a-Thr-32 [Beyotime, AF605]; or a 1:2000 dilution of the anti-actin antibody [Cali-bio, CB100997M]).

Techniques: Expressing, Over Expression, Western Blot, Real-time Polymerase Chain Reaction, Negative Control, Knockdown

Figure 4. FOXO3a down-regulates PRNP expression by binding to its promoter. (A) Two potential FOXO3a binding sites in the human PRNP promoter (dark background) at 21299 to 21292 and 21177 to 21170. (B) Potential FOXO3a binding sites in the Ovis aries and Bos taurus PRNP promoters (dark background). (C) and (D) EMSA showing that FOXO3a can bind to the human PRNP promoter. Compared with the control (lanes 1 and 2), FOXO3a bound to the PRNP promoter in a dose-dependent manner (lanes 3, 4 and 5), and this binding was abolished by a 50-fold excess of unlabeled probes (lanes 6 and 7) and mutation of the FOXO binding site (lanes 8 and 9) results in low affinity for FOXO3a. (E) Luciferase assay confirming that the human PRNP promoter recombinant has promoter-like activity. The pGL3-Basic and pGL3-Control plasmids were used as negative and positive controls, respectively. (F) Luciferase assay showing that FOXO1 and FOXO3a reduce the promoter activity of the PRNP promoter in the

Journal: PloS one

Article Title: IGF-1-induced enhancement of PRNP expression depends on the negative regulation of transcription factor FOXO3a.

doi: 10.1371/journal.pone.0071896

Figure Lengend Snippet: Figure 4. FOXO3a down-regulates PRNP expression by binding to its promoter. (A) Two potential FOXO3a binding sites in the human PRNP promoter (dark background) at 21299 to 21292 and 21177 to 21170. (B) Potential FOXO3a binding sites in the Ovis aries and Bos taurus PRNP promoters (dark background). (C) and (D) EMSA showing that FOXO3a can bind to the human PRNP promoter. Compared with the control (lanes 1 and 2), FOXO3a bound to the PRNP promoter in a dose-dependent manner (lanes 3, 4 and 5), and this binding was abolished by a 50-fold excess of unlabeled probes (lanes 6 and 7) and mutation of the FOXO binding site (lanes 8 and 9) results in low affinity for FOXO3a. (E) Luciferase assay confirming that the human PRNP promoter recombinant has promoter-like activity. The pGL3-Basic and pGL3-Control plasmids were used as negative and positive controls, respectively. (F) Luciferase assay showing that FOXO1 and FOXO3a reduce the promoter activity of the PRNP promoter in the

Article Snippet: Blocked with 5% nonfat milk in TBST (10 mM Tris, 150 mM NaCl, 0.1% Tween-20, pH 7.4) for 1 hour, the membrane was then incubated with specific primary antibodies over night at 4uC (i.e., a 1:1000 dilution of the anti-PrP monoclonal antibody 8H4 [Abcam, ab61409]; 1:1000 dilutions of monoclonal antibodies against FOXO1 [Beyotime, AF603], FOXO3a [Cell Signaling Technology, 75D8], phosphorylated FOXO1-Thr-24/FOXO3a-Thr-32 [Beyotime, AF605]; or a 1:2000 dilution of the anti-actin antibody [Cali-bio, CB100997M]).

Techniques: Expressing, Binding Assay, Control, Mutagenesis, Luciferase, Recombinant, Activity Assay

Figure 5. IGF-1 induces an increase in PRNP expression through the PI3K-Akt-FOXO3a pathway. (A) and (B) Translocation of FOXO3a induced by different treatments. Before the treatments, GFP-FOXO3a was located predominantly in the cytoplasm. In contrast, serum starvation or treatment with LY294002 induced the nuclear translocation of GFP-FOXO3a, whereas treatment with SP600125 or U0126 had no effect on the GFP- FOXO3a translocation. However, IGF-1 was able to induce the cytoplasmic retention of GFP-FOXO3a even under serum-free conditions, whereas treatment with LY294002 led to the nuclear retention of GFP-FOXO3a even in the presence of IGF-1. (C) and (D) Western blotting showing the relationship between the phosphorylation of FOXO3a and PRNP expression. Treatment with 50 and 100 ng/ml IGF-1 remarkably increased the phosphorylation of FOXO3a in both the SH-SY5Y and HeLa cell lines but caused little variation in the total level of FOXO3a. In accordance with this increase in the phosphorylation of FOXO3a, the PrPC protein level was also increased. All protein levels were normalized to actin. (E) Western blotting showing the relationship between the dephosphorylation of FOXO3a and PRNP expression. The phosphorylation of FOXO3a was maximally inhibited after treatment with LY294002 for 1 hour, and this inhibition was gradually reduced after 4 hours. In addition, the PrPc protein levels began to

Journal: PloS one

Article Title: IGF-1-induced enhancement of PRNP expression depends on the negative regulation of transcription factor FOXO3a.

doi: 10.1371/journal.pone.0071896

Figure Lengend Snippet: Figure 5. IGF-1 induces an increase in PRNP expression through the PI3K-Akt-FOXO3a pathway. (A) and (B) Translocation of FOXO3a induced by different treatments. Before the treatments, GFP-FOXO3a was located predominantly in the cytoplasm. In contrast, serum starvation or treatment with LY294002 induced the nuclear translocation of GFP-FOXO3a, whereas treatment with SP600125 or U0126 had no effect on the GFP- FOXO3a translocation. However, IGF-1 was able to induce the cytoplasmic retention of GFP-FOXO3a even under serum-free conditions, whereas treatment with LY294002 led to the nuclear retention of GFP-FOXO3a even in the presence of IGF-1. (C) and (D) Western blotting showing the relationship between the phosphorylation of FOXO3a and PRNP expression. Treatment with 50 and 100 ng/ml IGF-1 remarkably increased the phosphorylation of FOXO3a in both the SH-SY5Y and HeLa cell lines but caused little variation in the total level of FOXO3a. In accordance with this increase in the phosphorylation of FOXO3a, the PrPC protein level was also increased. All protein levels were normalized to actin. (E) Western blotting showing the relationship between the dephosphorylation of FOXO3a and PRNP expression. The phosphorylation of FOXO3a was maximally inhibited after treatment with LY294002 for 1 hour, and this inhibition was gradually reduced after 4 hours. In addition, the PrPc protein levels began to

Article Snippet: Blocked with 5% nonfat milk in TBST (10 mM Tris, 150 mM NaCl, 0.1% Tween-20, pH 7.4) for 1 hour, the membrane was then incubated with specific primary antibodies over night at 4uC (i.e., a 1:1000 dilution of the anti-PrP monoclonal antibody 8H4 [Abcam, ab61409]; 1:1000 dilutions of monoclonal antibodies against FOXO1 [Beyotime, AF603], FOXO3a [Cell Signaling Technology, 75D8], phosphorylated FOXO1-Thr-24/FOXO3a-Thr-32 [Beyotime, AF605]; or a 1:2000 dilution of the anti-actin antibody [Cali-bio, CB100997M]).

Techniques: Expressing, Translocation Assay, Western Blot, Phospho-proteomics, De-Phosphorylation Assay, Inhibition

Figure 6. Model for the regulation of PRNP in response to IGF-1. After cells are exposed to IGF-1, IGF-1R is activated, which then activates the PI3K-Akt pathway. The activated Akt then phosphorylates FOXO3a, leading to its translocation from the nucleus to the cytoplasm and thereby preventing FOXO3a from binding to the PRNP promoter (black arrows and streaks). With no or low levels of IGF-1 or in the presence of LY294002, the negative regulation of PI3K-Akt on FOXO3a is impaired. Then, FOXO3a is able to relocate to the nucleus, where it binds to the PRNP promoter and negatively regulates PRNP expression (red arrows and streaks). doi:10.1371/journal.pone.0071896.g006

Journal: PloS one

Article Title: IGF-1-induced enhancement of PRNP expression depends on the negative regulation of transcription factor FOXO3a.

doi: 10.1371/journal.pone.0071896

Figure Lengend Snippet: Figure 6. Model for the regulation of PRNP in response to IGF-1. After cells are exposed to IGF-1, IGF-1R is activated, which then activates the PI3K-Akt pathway. The activated Akt then phosphorylates FOXO3a, leading to its translocation from the nucleus to the cytoplasm and thereby preventing FOXO3a from binding to the PRNP promoter (black arrows and streaks). With no or low levels of IGF-1 or in the presence of LY294002, the negative regulation of PI3K-Akt on FOXO3a is impaired. Then, FOXO3a is able to relocate to the nucleus, where it binds to the PRNP promoter and negatively regulates PRNP expression (red arrows and streaks). doi:10.1371/journal.pone.0071896.g006

Article Snippet: Blocked with 5% nonfat milk in TBST (10 mM Tris, 150 mM NaCl, 0.1% Tween-20, pH 7.4) for 1 hour, the membrane was then incubated with specific primary antibodies over night at 4uC (i.e., a 1:1000 dilution of the anti-PrP monoclonal antibody 8H4 [Abcam, ab61409]; 1:1000 dilutions of monoclonal antibodies against FOXO1 [Beyotime, AF603], FOXO3a [Cell Signaling Technology, 75D8], phosphorylated FOXO1-Thr-24/FOXO3a-Thr-32 [Beyotime, AF605]; or a 1:2000 dilution of the anti-actin antibody [Cali-bio, CB100997M]).

Techniques: Translocation Assay, Binding Assay, Expressing

KEY RESOURCES TABLE

Journal: Cell reports

Article Title: Mitohormesis Primes Tumor Invasion and Metastasis

doi: 10.1016/j.celrep.2019.04.095

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Rabbit monoclonal anti-FOXO3a (75D8) , Cell Signaling Technology , Cat#2497; RRID:AB_836876.

Techniques: Virus, Recombinant, Plasmid Preparation, Transfection, Membrane, Cell Culture, Pore Size, Staining, Gene Expression, shRNA, Software

Quantitative proteomics by the Tandem Mass Tag (TMT) method

Journal: BMC Cancer

Article Title: Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells

doi: 10.1186/s12885-018-4974-5

Figure Lengend Snippet: Quantitative proteomics by the Tandem Mass Tag (TMT) method

Article Snippet: Antibodies against vitronectin 65/75 (D-8; #sc-74,484) and fibronectin (EP5; #sc-8422) were purchased from Santa Cruz Biotechnology (Dallas, TX).

Techniques: Quantitative Proteomics, Activity Assay, Coagulation

EOC-derived exosomes enhanced fibronectin and vitronectin expression in HPMCs through the transfer of miR-99a-5p. a Western blotting. HPMCs were transfected with miR-99a-5p or negative control miRNA. Thereafter, cell lysates were collected, and immunoblotting was performed with antibodies against fibronectin, vitronectin, or β-actin as a loading control. Representative blots from three independent experiments are shown. b After HPMCs were treated with IOSE- and EOC-derived exosomes at 100 μg/mL for 24 h, cell lysates were collected, and western blotting was performed as described above. c HPMCs transfected with negative control miRNA and anti-miR-99a-5p were treated with exosomes at 100 μg/mL for 24 h. Thereafter, cell lysates were collected, and western blotting was performed as described above. d Densitometric ratios of fibronectin, vitronectin, and β-actin expression. e Model. EOC-derived exosomes affect HPMCs through the transfer of miR-99a-5p. See text for details

Journal: BMC Cancer

Article Title: Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells

doi: 10.1186/s12885-018-4974-5

Figure Lengend Snippet: EOC-derived exosomes enhanced fibronectin and vitronectin expression in HPMCs through the transfer of miR-99a-5p. a Western blotting. HPMCs were transfected with miR-99a-5p or negative control miRNA. Thereafter, cell lysates were collected, and immunoblotting was performed with antibodies against fibronectin, vitronectin, or β-actin as a loading control. Representative blots from three independent experiments are shown. b After HPMCs were treated with IOSE- and EOC-derived exosomes at 100 μg/mL for 24 h, cell lysates were collected, and western blotting was performed as described above. c HPMCs transfected with negative control miRNA and anti-miR-99a-5p were treated with exosomes at 100 μg/mL for 24 h. Thereafter, cell lysates were collected, and western blotting was performed as described above. d Densitometric ratios of fibronectin, vitronectin, and β-actin expression. e Model. EOC-derived exosomes affect HPMCs through the transfer of miR-99a-5p. See text for details

Article Snippet: Antibodies against vitronectin 65/75 (D-8; #sc-74,484) and fibronectin (EP5; #sc-8422) were purchased from Santa Cruz Biotechnology (Dallas, TX).

Techniques: Derivative Assay, Expressing, Western Blot, Transfection, Negative Control, Control